The cost of oropharyngeal cancer in England: A retrospective hospital data analysis

Objectives To estimate the total costs of treating head and neck cancers, specifically oropharyngeal, laryngeal and oral cavity cancer, in secondary care facilities in England during the period 2006/2007 to 2010/2011. Design Patient records were extracted from an English hospital database to estimat...

Full description

Saved in:
Bibliographic Details
Published in:Clinical otolaryngology 2018-02, Vol.43 (1), p.223-229
Main Authors: Keeping, S.T., Tempest, M.J., Stephens, S.J., Carroll, S.M., Simcock, R., Jones, T.M., Shaw, R.
Format: Article
Language:English
Subjects:
Cancer
Cost analysis
cost burden
Cost estimates
Costs
Data analysis
Data processing
Epidemiology
Head & neck cancer
head and neck cancer
human papillomavirus
Laryngeal cancer
Oral cancer
Oral cavity
oral cavity cancer
Oropharyngeal cancer
Patients
prevention
resource use
Throat cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives To estimate the total costs of treating head and neck cancers, specifically oropharyngeal, laryngeal and oral cavity cancer, in secondary care facilities in England during the period 2006/2007 to 2010/2011. Design Patient records were extracted from an English hospital database to estimate the number of patients treated for oropharyngeal, laryngeal and oral cavity cancer in England. Identified resource use was linked to published United Kingdom cost estimates to quantify the reimbursement of treatment through the Payment by Results system. Setting Retrospective hospital data analysis. Participants From the hospital data, patient records of patients treated for oropharyngeal, laryngeal and oral cavity cancer were selected. Main outcome measures Annual total costs of treatment, stratified by inpatient and outpatient setting and by male and female patients. Results From 2006/2007 to 2010/2011, total costs of treatment across the three head and neck cancer sites were estimated to be approximately £309 million, with 90% attributable to inpatient care (bundled costs). Oropharyngeal cancer accounted for 37% of total costs. Costs and patient numbers increased over time, largely due to a rise in oropharyngeal cancer, where total costs increased from £17.21 million to £30.32 million, with over 1400 (52%) more inpatients treated in 2010/11 compared to 2006/07. Conclusions In 4 years, the number of patients with oropharyngeal cancer receiving some form of inpatient care increased by more than half, and associated costs increased by three quarters. This reinforces the case for prevention and early detection strategies to help contain this epidemiological and economic burden.
ISSN:1749-4478
1749-4486
DOI:10.1111/coa.12944